Extending treatment after liver transplant may benefit patients with hepatitis C recurrence

October 31, 2009

DETROIT - Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

"We found that patients who achieved a sustained virological response were more likely to have had extended treatment," says Kimberly Brown, M.D., Division head of Gastroenterology at Henry Ford Hospital and senior author of the study.

"In addition, prolonging treatment for 52 weeks after patients were virus negative, resulted in a relapse rate of only 8 percent." This is in contrast to typical relapse rates of 30-35 percent in non transplant patients treated with standard therapy.

Study results will be presented during an oral presentation Oct. 31 at the American Association for the Study of Liver Diseases' Annual Meeting in Boston.

The study looked at 241 consecutive liver transplant patients from 1999-2006. Patients were offered treatment if they tested positive hepatitis C, had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable immunosuppression for a minimum of three months. Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.

Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed.

After week 24 of treatment, 35 percent of patients who achieved a sustained virologic response became virus negative.

"These results call into question previous studies which suggested 'stop rules' at weeks 12 and 24 when there is no response to inferferon and ribravirin," says Dr. Brown. "Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance. We think this may be beneficial to extend treatment beyond the standard 48 weeks total."

According to the U.S. Department of Health & Human Services, more than 16,000 liver transplants were performed last year and there are currently almost 18,000 Americans on the liver transplant list.
-end-
EDITOR'S NOTE: Dr. Kimberly Brown and Dr. Matthew Moeller are available for interviews.

Funding: Henry Ford Hospital

EMBARGOED FOR RELEASE
9 a.m., EST, Saturday, Oct. 31, 2009

Henry Ford Health System

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.